National Institute on Drug Abuse; Notice of Closed Meeting, 50720-50721 [2021-19533]

Download as PDF 50720 Federal Register / Vol. 86, No. 173 / Friday, September 10, 2021 / Notices within 30-days of the date of this publication. Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to www.reginfo.gov/public/do/ PRAMain. Find this particular information collection by selecting ‘‘Currently under 30-day Review—Open for Public Comments’’ or by using the search function. ADDRESSES: FOR FURTHER INFORMATION CONTACT: Amy Williams, Director of the Office of Advocacy Relations (OAR), NCI, NIH, 31 Center Drive, Bldg. 31, Room 10A28, MSC 2580, Bethesda, MD 20892, call non-toll-free number 240–781–3406, or email your request, including your address, to amy.williams@nih.gov. This proposed information collection was previously published in the Federal Register on October 8, 2020, page 63565 (Vol. 85 FR 63565) and allowed 60 days for public comment. No public comments were received. The National Cancer Institute (NCI), National Institutes of Health, may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after SUPPLEMENTARY INFORMATION: ensure the advocates received property support by assessing satisfaction, expectations, involvement, barriers, and recruitment while working with the NCI. OAR continues to use the database system, which will allow this information to be collected electronically to match advocates easily and appropriately to NCI initiatives and activities as well as to assist NCI researchers in finding advocates to support their activities. In the previous three years, OAR has welcomed 49 advocates into our network. Advocates have contributed to over 30 activities, ranging widely in scope and duration. Several examples include speaking engagements, Task Force appointments, Steering Committee appointments, webinars, Advisory Board appointments, etc. These forms were previously approved as, ‘‘Generic Submission for Formative Research, Pretesting, Stakeholder Measures and Advocate Forms at NCI’’ (OMB #: 0925– 0641, Expiration Date: 1/31/2021). However, since OAR has not submitted Gen ICs for the past approvals this is being submitted as a new submission. OMB approval is requested for 3 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 16. October 1, 1995, unless it displays a currently valid OMB control number. In compliance with Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below. Proposed Collection: Stakeholder Measures and Advocate Forms at the National Cancer Institute (NCI), OMB #0925–NEW: Expiration Date XX/XX/ XXXX, NEW, National Cancer Institute (NCI), National Institutes of Health (NIH). Need and Use of Information Collection: The Office of Advocacy Relations (OAR) has collected data from different stakeholder constituencies: NIH and NCI staff, NCI-funded scientists and staff from universities and cancer centers, research advocates and their advocacy organizations, and members of scientific and professional societies and their organizations concerned about cancer. OAR uses the Profile Completion Questionnaire to capture applicant information such as basic contact information, age, gender, race and ethnicity, work focus, employment status, health experiences, and research advocacy experience. In addition, a post-activity survey is requested to ESTIMATED ANNUALIZED BURDEN HOURS Number of responses per respondent Average time per response (in hours) Total annual burden hour Type of respondent Profile Completion ............................. Survey ............................................... Individuals ........................................ Individuals ........................................ 30 15 1 1 30/60 5/60 15 1 Totals ......................................... ........................................................... ........................ 45 ........................ 16 Dated: September 2, 2021. Diane Kreinbrink, Project Clearance Liaison, National Cancer Institute, National Institutes of Health. [FR Doc. 2021–19544 Filed 9–9–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health jbell on DSKJLSW7X2PROD with NOTICES Number of respondents Form name National Institute on Drug Abuse; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, NIDA. VerDate Sep<11>2014 18:09 Sep 09, 2021 Jkt 253001 The meeting will be closed to the public as indicated below in accordance with the provisions set forth in sections 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the NATIONAL INSTITUTE ON DRUG ABUSE, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Board of Scientific Counselors, NIDA. Date: October 26, 2021. Time: 8:00 a.m. to 5:15 p.m. PO 00000 Frm 00027 Fmt 4703 Sfmt 4703 Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators. Place: National Institute on Drug Abuse, NIH, Biomedical Research Center, 251 Bayview Boulevard, Baltimore, MD 21224 (Virtual Meeting). Contact Person: Deon M. Harvey, Ph.D., Management Analyst, Office of the Scientific Director, National Institute on Drug Abuse, 251 Bayview Boulevard, Room 04A314, Baltimore, MD 21224, (443) 740–2466, deon.harvey@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) E:\FR\FM\10SEN1.SGM 10SEN1 Federal Register / Vol. 86, No. 173 / Friday, September 10, 2021 / Notices Dated: September 3, 2021. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2021–19533 Filed 9–9–21; 8:45 am] Center for Scientific Review; Notice of Closed Meetings BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. jbell on DSKJLSW7X2PROD with NOTICES Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Acute Renal Injury Sequelae in NICU Graduates (ARISING). Date: October 15, 2021. Time: 1:00 p.m. to 2:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Paul A. Rushing, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 7345, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, (301) 594–8895, rushingp@extra.niddk.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) Dated: September 7, 2021. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–19559 Filed 9–9–21; 8:45 am] BILLING CODE 4140–01–P VerDate Sep<11>2014 18:09 Sep 09, 2021 Jkt 253001 National Institutes of Health Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR–20– 131: Mammalian Models for Translational Research. Date: October 4, 2021. Time: 11:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Jeffrey Smiley, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6194, MSC 7804, Bethesda, MD 20892, 301–272– 4596, smileyja@csr.nih.gov. Name of Committee: Population Sciences and Epidemiology Integrated Review Group; Social Sciences and Population Studies: A Study Section. Date: October 5–6, 2021. Time: 10:00 a.m. to 6:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Suzanne Ryan, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3139, MSC 7770, Bethesda, MD 20892, (301) 435– 1712, ryansj@csr.nih.gov. Name of Committee: Musculoskeletal, Oral and Skin Sciences Integrated Review Group; Musculoskeletal Tissue Engineering Study Section. Date: October 12–13, 2021. Time: 9:00 a.m. to 9:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Srikanth Ranganathan, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 50721 Health, 6701 Rockledge Drive, Room 4214, MSC 7802, Bethesda, MD 20892, (301) 435– 1787, srikanth.ranganathan@nih.gov. Name of Committee: Cell Biology Integrated Review Group; Development—2 Study Section. Date: October 12–13, 2021. Time: 9:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Rass M. Shayiq, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2182, MSC 7818, Bethesda, MD 20892, (301) 435– 2359, shayiqr@csr.nih.gov. Name of Committee: Brain Disorders and Clinical Neuroscience Integrated Review Group; Clinical Neuroscience and Neurodegeneration Study Section. Date: October 13–14, 2021. Time: 8:30 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Alessandra C. Rovescalli, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Rm. 5205, MSC 7846, Bethesda, MD 20892, (301) 435– 1021, rovescaa@mail.nih.gov. Name of Committee: Brain Disorders and Clinical Neuroscience Integrated Review Group; Clinical Neuroimmunology and Brain Tumors Study Section. Date: October 14–15, 2021. Time: 9:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Aleksey Gregory Kazantsev, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5201, Bethesda, MD 20817, 301–435–1042, aleksey.kazantsev@nih.gov. Name of Committee: Infectious Diseases and Immunology A Integrated Review Group; Pathogenic Eukaryotes Study Section. Date: October 14–15, 2021. Time: 9:00 a.m. to 8:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Tera Bounds, DVM, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3198, MSC 7808, Bethesda, MD 20892, 301–435– 2306, boundst@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR 19– 367: Maximizing Investigators’ Research Award. Date: October 14–15, 2021. Time: 10:00 a.m. to 8:00 p.m. E:\FR\FM\10SEN1.SGM 10SEN1

Agencies

[Federal Register Volume 86, Number 173 (Friday, September 10, 2021)]
[Notices]
[Pages 50720-50721]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-19533]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the Board of Scientific 
Counselors, NIDA.
    The meeting will be closed to the public as indicated below in 
accordance with the provisions set forth in sections 552b(c)(6), Title 
5 U.S.C., as amended for the review, discussion, and evaluation of 
individual intramural programs and projects conducted by the NATIONAL 
INSTITUTE ON DRUG ABUSE, including consideration of personnel 
qualifications and performance, and the competence of individual 
investigators, the disclosure of which would constitute a clearly 
unwarranted invasion of personal privacy.

    Name of Committee: Board of Scientific Counselors, NIDA.
    Date: October 26, 2021.
    Time: 8:00 a.m. to 5:15 p.m.
    Agenda: To review and evaluate personnel qualifications and 
performance, and competence of individual investigators.
    Place: National Institute on Drug Abuse, NIH, Biomedical 
Research Center, 251 Bayview Boulevard, Baltimore, MD 21224 (Virtual 
Meeting).
    Contact Person: Deon M. Harvey, Ph.D., Management Analyst, 
Office of the Scientific Director, National Institute on Drug Abuse, 
251 Bayview Boulevard, Room 04A314, Baltimore, MD 21224, (443) 740-
2466, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)


[[Page 50721]]


    Dated: September 3, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-19533 Filed 9-9-21; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.